FMC
Develops and sells crop-protection products for growers worldwide.
Something off on this page? Send us feedback.
Profile
Sells insecticides, herbicides, fungicides, biologicals, crop nutrition, and seed treatments through one global agricultural-sciences segment. Its portfolio combines conventional chemistry with plant-health products and depends on product registrations, intellectual property, manufacturing inputs, and access to growers.
Operates one global agricultural-sciences segment supplying insecticides, herbicides, fungicides, biologicals, crop nutrition, and seed-treatment products, grouped as plant health. Products serve growers across North America, Latin America, EMEA, and Asia.
Research focuses on discovering insecticide, herbicide, and fungicide active ingredients. The portfolio expanded through Cheminova, DuPont crop-protection assets, and BioPhero, combining conventional chemicals with biological and pheromone capabilities.
The business depends on registrations, intellectual property, discovery and development, manufacturing inputs, and access to growers across regions. It also plans to divest its India commercial business while retaining active-ingredient manufacturing there.
Company facts
Key statistics
Year to date −21.1% · Average volume (30d) 3.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 4, 2026 | Seaport Global | Target | $55 | $21 | |
| Aug 3, 2026 | RBC Capital | Reiterate | Sector Perform | $14 | $11 |
| Jul 31, 2026 | Morgan Stanley | Reiterate | Equal Weight | $15.50 | $12 |
| Jul 31, 2026 | Goldman Sachs | Reiterate | Buy | $43 | $18 |
| Jul 27, 2026 | Barclays | Reiterate | Underweight | $13 | $11 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $0.22 | $0.26 | +18.0% | $895.1M | $867.1M | −3.1% | +18.18% |
| Apr 29, 2026Q1 FY26 | −$0.39 | −$0.23 | +41.0% | $745.4M | $762.4M | +2.3% | +4.98% |
| Feb 4, 2026Q4 FY25 | $1.21 | $1.20 | −0.8% | $1.15B | $1.08B | −5.9% | −19.54% |
| Oct 29, 2025Q3 FY25 | $0.85 | $0.89 | +4.7% | $1.15B | $489.0M | −57.5% | −46.52% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $791.4M | $1.05B | $489.0M | $1.14B | $758.6M | $867.1M | |
| Gross profit | $317.0M | $407.3M | $75.7M | $483.0M | $246.6M | $342.1M | |
| Operating income | $76.3M | $164.1M | −$467.3M | −$1.66B | −$81.0M | −$119.7M | |
| Net income | −$15.5M | $66.7M | −$569.3M | −$1.72B | −$281.3M | −$186.6M | |
| Diluted EPS | −$0.12 | $0.53 | −$4.52 | −$13.77 | −$2.25 | −$1.48 | |
| Gross margin | 40.1% | 38.8% | 15.5% | 42.5% | 32.5% | 39.5% | |
| Operating margin | 9.6% | 15.6% | -95.6% | -146.0% | -10.7% | -13.8% |
Fiscal years (4-quarter sums)FY21 $5.05B · FY22 $5.80B · FY23 $4.49B · FY24 $4.25B · FY25 $3.47B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $476.6M · Total debt $4.28B · Total assets $9.14B · Shareholders' equity $1.64B
Dividends
Raised for 19 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 30, 2026 | Jun 30 | Jul 16 | $0.08 | |
| Mar 31, 2026 | Mar 31 | Apr 16 | $0.08 | |
| Dec 31, 2025 | Dec 31 | Jan 15 | $0.08 | cut from $0.58 |
| Sep 30, 2025 | Sep 30 | Oct 16 | $0.58 | |
| Jun 30, 2025 | Jun 30 | Jul 17 | $0.58 | |
| Mar 31, 2025 | Mar 31 | Apr 17 | $0.58 | |
| Dec 31, 2024 | Dec 31 | Jan 16 | $0.58 | |
| Sep 30, 2024 | Sep 30 | Oct 17 | $0.58 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 125.23M · Float 123.82M · 98.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 21.54M | 17.20% | 13F | Aug 7, 2026 |
| AQR Capital Management LLC | 8.02M | 6.41% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 7.72M | 6.16% | 13F | Aug 13, 2026 |
| State Street Corporation | 6.51M | 5.20% | 13G | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.76M | 4.60% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 4, 2026 | Michael F. Barry | director | +18,072 | $13.83 |
| Nov 13, 2025 | John Mitchell Raines | director | +7,000 | $13.77 |
| Nov 5, 2025 | Carol Anthony Davidson | director | +10,000 | $13.60 |
| Sep 29, 2025 | Jacqueline Scanlan | officer: Executive VP & Chief HRO | −3,790 | $34.00 |
Peers
- Corteva
Broad crop-protection overlap across chemistries and biologicals
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| FMC | $11.32 | 0.00% | $1.42B | — | 8.0 | 0.4 | −17.5% |
| Corteva | $83.90 | −0.04% | $56.11B | 55.6 | 21.4 | 3.2 | −1.2% |
| Median | 55.6 | 21.4 | 3.2 | −1.2% |